Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
CAPR has been in the news recently: Capricor Therapeutics, Inc. investors who purchased securities between October 9, 2024, and July 10, 2025, are reminded of a lead plaintiff deadline on September 15, 2025, for a class action lawsuit. Multiple law firms, including Rosen Law Firm and Gross Law Firm, are inviting affected shareholders to participate in the lawsuit due to reported losses during this period.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
